Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News in Brief
  • Published:

News In Brief

Nature Biotechnology volume 23, pages 515–516 (2005)Cite this article

An Erratum to this article was published on 01 July 2005

This article has been updated

EMEA fee hike

On March 31, the European Commission (EC) proposed to raise fees for the authorization of pharmaceuticals at the European Medicines Agency (EMEA). Although the agency received 51 new applications in 2004—a sharp rise from the 39 received in 2003—the increase was not introduced specifically to deal with higher numbers of applications as they are expected to slow. Instead, the fee hike would mainly cover additional tasks such as more intensive post-authorization monitoring. These will be undertaken starting in November 2005 as the new legislation comes into force. The annual fees will go up by 10% as of 2006 and a new and variable fee for yet unspecified 'scientific services' will be introduced. In addition, biotech companies falling in the small and medium-sized enterprises category would get deferments and discounts. The industry's total contribution to EMEA's budget would thus increase slightly from 68.1% this year to 68.4% in 2006. Another measure would introduce new fees that would range between those for new products and traditional generics for follow-on biologics, known as 'biosimilars.' The European bioindustry association EuropaBio in Brussels welcomes the new fee as an acknowledgment that biosimilars need more review than traditional generics. PV

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 01 July 2005

    Nat. Biotechnol. 23, 516 (2005) Nomura Research & Advisory was incorrectly said to be “the research arm of brokerage giant Nomura Securities.” It should have said it was “a subsidiary of Nomura Holdings.”

Rights and permissions

Reprints and permissions

About this article

Cite this article

News In Brief. Nat Biotechnol 23, 515–516 (2005). https://doi.org/10.1038/nbt0505-515

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0505-515

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing